Loss of Rab8a-Dependent Tethering of Lipid Droplets to Mitochondria Contributes to Hypoxia–Reoxygenation Injury

Abstract

Tethering of lipid droplets (LDs) to mitochondria facilitates fatty acid oxidation and is a key adaptive response that helps cardiomyocytes cope with hypoxia–reoxygenation (HR) stress. However, the molecular mechanisms regulating these interactions during ischemia are not fully understood. We found that HR significantly decreased cardiomyocyte expression and phosphorylation of Rab8a, a small GTPase that interacts with the LD-associated protein perilipin 5 to mediate LD–mitochondria tethering. Using long-chain fatty acid (LCFA) tracking assays we confirmed that loss of Rab8a disrupted physical contact between these organelles to impair the transfer of LCFA from LDs to mitochondria. Furthermore, HR led to the accumulation of intracellular lipids via a combination of both lipolysis and lipophagy, resulting in metabolic stress. To counteract this defect, we evaluated the therapeutic potential of ALY688, a peptide agonist of adiponectin receptors known to stimulate the AMPK–Rab8a signaling axis. Our data indicated that treatment with ALY688 preserved Rab8a expression during HR, thereby maintaining LD–mitochondria interactions and improving metabolic function. These findings uncover a novel Rab8a-dependent mechanism regulating lipid metabolism under ischemic/hypoxic stress and highlight the potential of adiponectin mimetics like ALY688 to mitigate metabolic dysfunction in ischemic heart disease.

Keywords

adiponectin / cardiomyocyte / hypoxia / ischemia / lipophagy / lipolysis / lipid droplet / mitochondria / reoxygenation

References

[1] G. D. Lopaschuk, Q. G. Karwi, R. Tian, A. R. Wende, and E. D. Abel, “Cardiac Energy Metabolism in Heart Failure,” Circulation Research 128, no. 10 (2021): 1487–1513.

[2] W. D. Watson, P. G. Green, A. J. M. Lewis, et al., “Retained Metabolic Flexibility of the Failing Human Heart,” Circulation 148, no. 2 (2023): 109–123.

[3] S. Neubauer, “The Failing Heart–an Engine out of Fuel,” N Engl J Med 356, no. 11 (2007): 1140–1151.

[4] Q. Sun, Q. G. Karwi, N. Wong, and G. D. Lopaschuk, “Advances in Myocardial Energy Metabolism: Metabolic Remodelling in Heart Failure and Beyond,” Cardiovascular Research 120, no. 16 (2024): 1996–2016.

[5] B. Zhou and R. Tian, “Mitochondrial Dysfunction in Pathophysiology of Heart Failure,” Journal of Clinical Investigation 128, no. 9 (2018): 3716–3726.

[6] Q. Liu, J. C. Docherty, J. C. Rendell, A. S. Clanachan, and G. D. Lopaschuk, “High Levels of Fatty Acids Delay the Recovery of Intracellular pH and Cardiac Efficiency in Post-ischemic Hearts by Inhibiting Glucose Oxidation,” Journal of the American College of Cardiology 39, no. 4 (2002): 718–725.

[7] S. C. Kolwicz, Jr., L. Liu, I. J. Goldberg, and R. Tian, “Enhancing Cardiac Triacylglycerol Metabolism Improves Recovery from Ischemic Stress,” Diabetes 64, no. 8 (2015): 2817–2827.

[8] I. J. Goldberg, C. M. Trent, and P. C. Schulze, “Lipid Metabolism and Toxicity in the Heart,” Cell Metab 15, no. 6 (2012): 805–812.

[9] A. Zadoorian, X. Du, and H. Yang, “Lipid Droplet Biogenesis and Functions in Health and Disease,” Nat Rev Endocrinol 19, no. 8 (2023): 443–459.

[10] L. Da Dalt, A. G. Cabodevilla, I. J. Goldberg, and G. D. Norata, “Cardiac Lipid Metabolism, Mitochondrial Function, and Heart Failure,” Cardiovascular Research 119, no. 10 (2023): 1905–1914.

[11] J. A. Olzmann and P. Carvalho, “Dynamics and Functions of Lipid Droplets,” Nat Rev Mol Cell Biol 20, no. 3 (2019): 137–155.

[12] P. C. Schulze, K. Drosatos, and I. J. Goldberg, “Lipid Use and Misuse by the Heart,” Circulation Research 118, no. 11 (2016): 1736–1751.

[13] Y. Getiye, T. A. Rice, B. D. Phillips, D. F. Carrillo, and G. He, “Dysregulated Lipolysis and Lipophagy in Lipid Droplets of Macrophages From High Fat Diet-fed Obese Mice,” J Cell Mol Med 26, no. 18 (2022): 4825–4836.

[14] U. Kintscher, A. Foryst-Ludwig, G. Haemmerle, and R. Zechner, “The Role of Adipose Triglyceride Lipase and Cytosolic Lipolysis in Cardiac Function and Heart Failure,” Cell Rep Med 1, no. 1 (2020): 100001.

[15] I. J. Goldberg, K. Reue, N. A. Abumrad, et al., “Deciphering the Role of Lipid Droplets in Cardiovascular Disease: A Report From the 2017 National Heart, Lung, and Blood Institute Workshop,” Circulation 138, no. 3 (2018): 305–315.

[16] R. Zechner, F. Madeo, and D. Kratky, “Cytosolic Lipolysis and Lipophagy: Two Sides of the Same Coin,” Nat Rev Mol Cell Biol 18, no. 11 (2017): 671–684.

[17] M. Boutant, S. S. Kulkarni, M. Joffraud, et al., “Mfn2 is critical for brown adipose tissue thermogenic function,” Embo J 36, no. 11 (2017): 1543–1558.

[18] B. Kien, S. Kolleritsch, N. Kunowska, et al., “Lipid Droplet-mitochondria Coupling via perilipin 5 Augments respiratory Capacity but Is Dispensable for FA Oxidation,” Journal of Lipid Research 63, no. 3 (2022): 100172.

[19] L. Hu, D. Tang, B. Qi, et al., “Mfn2/Hsc70 Complex Mediates the Formation of Mitochondria-Lipid Droplets Membrane Contact and Regulates Myocardial Lipid Metabolism,” Advanced Science 11, no. 14 (2024): 2307749.

[20] Q. Ouyang, Q. Chen, S. Ke, et al., “Rab8a as a Mitochondrial Receptor for Lipid Droplets in Skeletal Muscle,” Developmental Cell 58, no. 4 (2023): 289–305, e6.

[21] X. Ao, L. Zou, and Y. Wu, “Regulation of Autophagy by the Rab GTPase Network,” Cell Death & Differentiation 21, no. 3 (2014): 348–358.

[22] L. Wu, D. Xu, L. Zhou, et al., “Rab8a-AS160-MSS4 regulatory Circuit Controls Lipid Droplet Fusion and Growth,” Dev Cell 30, no. 4 (2014): 378–393.

[23] A. Bezawork-Geleta, C. J. Devereux, S. N. Keenan, et al., “Proximity proteomics reveals a mechanism of fatty acid transfer at lipid droplet-mitochondria- endoplasmic reticulum contact sites,” Nature Communications 16, no. 1 (2025): 2135.

[24] B. Schroeder, R. J. Schulze, S. G. Weller, A. C. Sletten, C. A. Casey, and M. A. McNiven, “The Small GTPase Rab7 as a central Regulator of Hepatocellular Lipophagy,” Hepatology 61, no. 6 (2015): 1896–1907.

[25] K. Kanerva, R. L. Uronen, T. Blom, et al., “LDL Cholesterol Recycles to the Plasma Membrane via a Rab8a-Myosin5b-actin-dependent Membrane Transport Route,” Dev Cell 27, no. 3 (2013): 249–262.

[26] K. M. Holzem, K. C. Vinnakota, V. K. Ravikumar, et al., “Mitochondrial structure and function are not different between nonfailing donor and end-stage failing human hearts,” The FASEB Journal 30, no. 8 (2016): 2698–2707.

[27] Q. Chen, P. Rong, D. Xu, et al., “Rab8a Deficiency in Skeletal Muscle Causes Hyperlipidemia and Hepatosteatosis by Impairing Muscle Lipid Uptake and Storage,” Diabetes 66, no. 9 (2017): 2387–2399.

[28] X. Lei, S. Qiu, G. Yang, and Q. Wu, “Adiponectin and metabolic cardiovascular diseases: Therapeutic opportunities and challenges,” Genes Dis 10, no. 4 (2023): 1525–1536.

[29] Y. Zhang, X. L. Wang, J. Zhao, et al., “Adiponectin Inhibits Oxidative/Nitrative Stress During Myocardial Ischemia and Reperfusion via PKA Signaling,” Am J Physiol Endocrinol Metab 305, no. 12 (2013): E1436–E1443.

[30] E. Tam, M. Ouimet, and G. Sweeney, “Cardioprotective Effects of Adiponectin-Stimulated Autophagy,” J Lipid Atheroscler 14, no. 1 (2025): 40–53.

[31] S. Cho, K. Dadson, H. K. Sung, et al., “Cardioprotection by the Adiponectin Receptor Agonist ALY688 in a Preclinical Mouse Model of Heart Failure With Reduced Ejection Fraction (HFrEF),” Biomedicine & Pharmacotherapy 171 (2024): 116119.

[32] Y. Kim, J. H. Lim, E. N. Kim, et al., “Adiponectin Receptor Agonist Ameliorates Cardiac Lipotoxicity via Enhancing Ceramide Metabolism in Type 2 Diabetic Mice,” Cell Death & Disease 13, no. 3 (2022): 282.

[33] D. Qi and L. H. Young, “AMPK: Energy Sensor and Survival Mechanism in the Ischemic Heart,” Trends Endocrinol Metab 26, no. 8 (2015): 422–429.

[34] K. Zhang, J. Gan, B. Wang, et al., “FGF21 protects Against HFpEF by Improving Cardiac Mitochondrial Bioenergetics in Mice,” Nature Communications 16, no. 1 (2025): 1661.

[35] L. Yang, X. Jia, D. Fang, et al., “Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells,” International Journal of Molecular Sciences 23, no. 11 (2022): 5986.

[36] C. Gaud, B. CS, A. Nguyen, et al., “BioPAN: A Web-based Tool to Explore Mammalian Lipidome Metabolic Pathways on LIPID MAPS,” F1000Res 10 (2021): 4.

[37] S. Zhang, X. Peng, S. Yang, et al., “The Regulation, Function, and Role of Lipophagy, a Form of Selective Autophagy, in Metabolic Disorders,” Cell death & disease 13, no. 2 (2022): 132.

[38] T. Laval and M. Ouimet, “A Role for Lipophagy in Atherosclerosis,” Nature Reviews Cardiology 20, no. 7 (2023): 431–432.

[39] C. J. Rosado, D. Mijaljica, I. Hatzinisiriou, M. Prescott, and R. J. Devenish, “Rosella: A Fluorescent pH-biosensor for Reporting Vacuolar Turnover of Cytosol and Organelles in Yeast,” Autophagy 4, no. 2 (2008): 205–213.

[40] T. Laval, N. Joyce, D. Boucher, et al., “A Rosella-PLIN2 knock-in mouse reveals lipophagy and immunometabolic interplay in atherosclerosis,” Autophagy Published online June 3, 2026.

[41] J. Tang, N. Yoon, K. Dadson, et al., “Impaired autophagy flux contributes to enhanced ischemia reperfusion injury in the diabetic heart,” Autophagy Reports 3, no. 1 (2024): 2330327.

[42] I. Y. Benador, M. Veliova, M. Liesa, and O. S. Shirihai, “Mitochondria Bound to Lipid Droplets: Where Mitochondrial Dynamics Regulate Lipid Storage and Utilization,” Cell metabolism 29, no. 4 (2019): 827–835.

[43] G. E. Miner, C. M. So, W. Edwards, et al., “PLIN5 interacts With FATP4 at Membrane Contact Sites to Promote Lipid Droplet-to-mitochondria Fatty Acid Transport,” Developmental Cell 58, no. 14 (2023): 1250–1265, e6.

[44] V. I. Gallardo-Montejano, C. Yang, L. Hahner, et al., “Perilipin 5 Links Mitochondrial Uncoupled Respiration in Brown Fat to Healthy White Fat Remodeling and Systemic Glucose Tolerance,” Nature Communications 12, no. 1 (2021): 3320.

[45] H. Wang, U. Sreenivasan, H. Hu, et al., “Perilipin 5, a Lipid Droplet-associated Protein, Provides Physical and Metabolic Linkage to Mitochondria,” Journal of Lipid Research 52, no. 12 (2011): 2159–2168.

[46] A. S. Rambold, S. Cohen, and J. Lippincott-Schwartz, “Fatty Acid Trafficking in Starved Cells: Regulation by Lipid Droplet Lipolysis, Autophagy, and Mitochondrial Fusion Dynamics,” Dev Cell 32, no. 6 (2015): 678–692.

[47] H. Stenmark, “Rab GTPases as Coordinators of Vesicle Traffic,” Nature Reviews Molecular Cell Biology 10, no. 8 (2009): 513–525.

[48] A. Herms, M. Bosch, B. J. Reddy, et al., “AMPK Activation Promotes Lipid Droplet Dispersion on Detyrosinated Microtubules to Increase Mitochondrial Fatty Acid Oxidation,” Nat Commun 6 (2015): 7176.

[49] D. Da Eira, S. Jani, H. Sung, G. Sweeney, and R. B. Ceddia, “Effects of the Adiponectin Mimetic Compound ALY688 on Glucose and Fat Metabolism in Visceral and Subcutaneous Rat Adipocytes,” Adipocyte 9, no. 1 (2020): 550–562.

[50] J. Du, T. Lan, H. Liao, et al., “CircNFIB Inhibits Tumor Growth and Metastasis Through Suppressing MEK1/ERK Signaling in Intrahepatic Cholangiocarcinoma,” Molecular cancer 21, no. 1 (2022): 18.

[51] X. Chen, H. Wu, Y. Liu, L. Liu, S. R. Houser, and W. E. Wang, “Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?,” Circulation 149, no. 20 (2024): 1598–1610.

[52] L. Han, D. Huang, S. Wu, et al., “Lipid Droplet-associated lncRNA LIPTER Preserves Cardiac Lipid Metabolism,” Nature Cell Biology 25, no. 7 (2023): 1033–1046.

[53] J. Ke, J. Pan, H. Lin, et al., “Targeting Rab7-Rilp Mediated Microlipophagy Alleviates Lipid Toxicity in Diabetic Cardiomyopathy,” Adv Sci (Weinh) 11, no. 29 (2024): e2401676.

[54] W. Du, L. Zhang, A. Brett-Morris, et al., “HIF Drives Lipid Deposition and Cancer in ccRCC via Repression of Fatty Acid Metabolism,” Nat Commun 8, no. 1 (2017): 1769.

[55] R. C. Sun and N. C. Denko, “Hypoxic Regulation of Glutamine Metabolism Through HIF1 and SIAH2 Supports Lipid Synthesis That Is Necessary for Tumor Growth,” Cell Metab 19, no. 2 (2014): 285–292.

[56] K. Bensaad, E. Favaro, C. A. Lewis, et al., “Fatty Acid Uptake and Lipid Storage Induced by HIF-1alpha Contribute to Cell Growth and Survival After Hypoxia-reoxygenation,” Cell Rep 9, no. 1 (2014): 349–365.

[57] J. Krishnan, M. Suter, R. Windak, et al., “Activation of a HIF1alpha-PPARgamma Axis Underlies the Integration of Glycolytic and Lipid Anabolic Pathways in Pathologic Cardiac Hypertrophy,” Cell Metab 9, no. 6 (2009): 512–524.

[58] G. L. Semenza, “Hypoxia-inducible factors in physiology and medicine,” Cell 148, no. 3 (2012): 399–408.

[59] G. F. Grabner, H. Xie, M. Schweiger, and R. Zechner, “Lipolysis: Cellular mechanisms for lipid mobilization from fat stores,” Nat Metab 3, no. 11 (2021): 1445–1465.

[60] Y. Gao, W. Zhang, L. Q. Zeng, et al., “Exercise and Dietary Intervention Ameliorate High-fat Diet-induced NAFLD and Liver Aging by Inducing Lipophagy,” Redox Biol 36 (2020): 101635.

[61] D. Das, M. Sharma, D. Gahlot, et al., “VPS4A is the Selective Receptor for Lipophagy in Mice and Humans,” Molecular Cell 84, no. 22 (2024): 4436–4453, e8.

[62] J. Chung, J. Park, Z. W. Lai, et al., “The Troyer syndrome Protein Spartin Mediates Selective Autophagy of Lipid Droplets,” Nature Cell Biology 25, no. 8 (2023): 1101–1110.

[63] M. Pu, W. Zheng, H. Zhang, et al., “ORP8 acts as a Lipophagy Receptor to Mediate Lipid Droplet Turnover,” Protein Cell 14, no. 9 (2023): 653–667.

[64] Y. Li, P. Yang, L. Zhao, et al., “CD36 plays a Negative Role in the Regulation of Lipophagy in Hepatocytes Through an AMPK-dependent Pathway,” J Lipid Res 60, no. 4 (2019): 844–855.

[65] T. B. Nguyen, S. M. Louie, J. R. Daniele, et al., “DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function During Starvation-Induced Autophagy,” Developmental Cell 42, no. 1 (2017): 9–21, e5.

[66] A. M. Valm, S. Cohen, W. R. Legant, et al., “Applying systems-level spectral imaging and analysis to reveal the organelle interactome,” Nature 546, no. 7656 (2017): 162–167.

[67] Q. Wu, M. Zhao, X. He, et al., “Acetylcholine Reduces Palmitate-induced Cardiomyocyte Apoptosis by Promoting Lipid Droplet Lipolysis and perilipin 5-mediated Lipid Droplet-mitochondria Interaction,” Cell Cycle 20, no. 18 (2021): 1890–1906.

[68] Y. Meng, D. Guo, L. Lin, et al., “Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance β-oxidation and tumor cell proliferation,” Nat Metab 6, no. 6 (2024): 1092–1107.

[69] I. Y. Benador, M. Veliova, K. Mahdaviani, et al., “Mitochondria Bound to Lipid Droplets Have Unique Bioenergetics, Composition, and Dynamics That Support Lipid Droplet Expansion,” Cell metabolism 27, no. 4 (2018): 869–885, e6.

[70] N. K. Talari, U. Mattam, N. K. Meher, et al., “Lipid-droplet Associated Mitochondria Promote Fatty-acid Oxidation Through a Distinct Bioenergetic Pattern in Male Wistar Rats,” Nat Commun 14, no. 1 (2023): 766.

[71] Z. Nichtová, C. Fernandez-Sanz, L. De, S. Fuente, et al., “Enhanced Mitochondria-SR Tethering Triggers Adaptive Cardiac Muscle Remodeling,” Circulation Research 132, no. 11 (2023): e171–e187.

[72] Y. Guo, Z. Wang, X. Qin, et al., “Enhancing Fatty Acid Utilization Ameliorates Mitochondrial Fragmentation and Cardiac Dysfunction via Rebalancing Optic Atrophy 1 Processing in the Failing Heart,” Cardiovascular Research 114, no. 7 (2018): 979–991.

[73] Y. Xu, Y. Zhang, W. Sun, et al., “Characteristics of different lipid droplet-mitochondrial contacts patterns during lipid droplet metabolism in T2DM-induced MASLD,” Scientific Reports 15, no. 1 (2025): 3399.

[74] L. G. Straub and P. E. Scherer, “Metabolic Messengers: Adiponectin,” Nat Metab 1, no. 3 (2019): 334–339.

[75] N. E. Sanjana, O. Shalem, and F. Zhang, “Improved Vectors and Genome-wide Libraries for CRISPR Screening,” Nat Methods 11, no. 8 (2014): 783–784.

[76] M. Ouimet, H. N. Ediriweera, U. M. Gundra, et al., “MicroRNA-33-dependent Regulation of Macrophage Metabolism Directs Immune Cell Polarization in Atherosclerosis,” Journal of Clinical Investigation 125, no. 12 (2015): 4334–4348.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.